Drug intelligence / Profile preview

PF-07868489

Development stage: Discontinued
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

PF-07868489 is an investigational recombinant human IgG1 monoclonal antibody developed by Pfizer for the treatment of pulmonary arterial hypertension (PAH). Its mechanism of action involves targeting and neutralizing bone morphogenetic protein 9 (BMP9, also known as GDF2), a member of the TGF-beta superfamily implicated in vascular remodeling and endothelial function. The drug is administered via subcutaneous injection and is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity profile, and preliminary efficacy in both healthy adults and patients with PAH[1][2][3][4][5][6][7][8].

Other names: anti-BMP9 antibodyanti-BMP-9 antibodyanti-BMP 9 antibody

Targets

BMP9 (Bone morphogenetic protein 9)

Beyond the preview

Go deeper on PF-07868489.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07868489.